<DOC>
	<DOCNO>NCT02809768</DOCNO>
	<brief_summary>The purpose study determine effect concomitant administration fluconazole , itraconazole , rifampin pharmacokinetics ( PK ) single 20-mg dose avatrombopag healthy participant .</brief_summary>
	<brief_title>Study Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole , Itraconazole , Rifampin Healthy Subjects</brief_title>
	<detailed_description>This study single center , open-label , drug-drug interaction study healthy participant . The study consist 3 part : In Part A , effect steady-state dose moderate inhibitor CYP2C9 CYP3A ( fluconazole ) single-dose PK avatrombopag assess . In Part B , effect steady-state dose strong CYP3A inhibitor ( itraconazole ) single-dose PK avatrombopag assess . In Part C , effect steady-state dose strong CYP3A moderate CYP2C9 inducer ( rifampin ) single-dose PK avatrombopag assess . Each Part study consist 2 phase : Pretreatment Treatment . The Pretreatment Phase consist 2 period : Screening Baseline Period 1.The Treatment Phase consist 2 treatment period : Treatment Period 1 ( administration single oral dose avatrombopag 20 mg alone fed condition ) ; Treatment Period 2 ( administration oral dos inhibitor inducer alone concomitant administration single oral dose avatrombopag 20 mg inhibitor inducer [ fluconazole Part A , itraconazole Part B , rifampin Part C ] feed condition ) .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>1 . Platelet count lower limit normal 300 × 10^9/L , inclusive , Screening Baseline . 2 . Nonsmoking , male female , age ≥18 year ≤55 year old . 3 . Body mass index ( BMI ) &gt; 18 ≤32 kg/m^2 Screening . 4 . Females must pregnant Screening documented negative serum beta human chorionic gonadotropin ( βhCG ) test minimum sensitivity 25 IU/L equivalent unit βhCG Baseline document negative urine pregnancy test result . 1 . Failure discontinue use agent associate high risk thrombosis ( include estrogen contain oral contraceptive ) within least 30 day dose . 2 . Evidence organ dysfunction clinically significant deviation normal medical history ( e.g. , history splenectomy ) ; history arterial venous thrombosis , include partial complete thromboses ( e.g. , stroke , transient ischemic attack , myocardial infarction , deep vein thrombosis , pulmonary embolism ) ; know family history hereditary thrombophilic disorder ( e.g. , Factor V Leiden , antithrombin III deficiency ) . 3 . Hemoglobin less low limit normal Screening Baseline Period 1 . 4 . Liver function test ( alanine transaminase [ ALT ] , aspartate transaminase [ AST ] , total bilirubin ) great upper limit normal Screening Baseline Period 1 . 5 . Any history gastrointestinal surgery may affect pharmacokinetics ( PK ) profile avatrombopag ( e.g. , hepatectomy , nephrectomy , cholecystectomy digestive organ resection ) Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>Pharmacokinetic Drug-Drug Interaction</keyword>
	<keyword>Avatrombopag</keyword>
</DOC>